RESUMO
BACKGROUND: The metabolic syndrome is associated with increased risk for both diabetes and coronary artery disease, which insulin resistance alone does not satisfactorily explain. We propose an additional and complementary underlying mechanism of glucocorticoid resistance. RESULTS: Using acanthosis nigricans (AN) and skin vasoconstrictor (SVC) response to topically applied beclomethasone dipropionate as markers of insulin and glucocorticoid resistance, respectively, we compared anthropometric, biochemical, pro-inflammatory markers and the SVC response in subjects with AN in two studies: STUDY 1 was used to compare subjects with AN (Grade 4, n = 32), with those without AN (n = 68) while STUDY 2 compared these responses among a cross-section of diabetic patients (n = 109) with varying grades of AN (grade 0, n = 30; grade 1, n = 24; grade 2, n = 18; grade 3, n = 25; grade 4, n = 12). FINDINGS: In both studies there was an inverse relationship between AN Grade 4 and the SVC response, (P < 0.001). In STUDY 1, AN Grade 4 was associated with age, waist circumference, BMI, fasting blood glucose, plasma lipids and hs-CRP (P < 0.05). SVC was an independent predictor of CRP and those with combined AN and a negative SVC response, CRP levels were highest. In Study 2 when the SVC response in subjects with type 2 diabetes mellitus with varying degrees of AN was studied, it showed that for any degree of AN, the SVC response is more likely to be negative and was independent of gender and ethnicity. CONCLUSION: An absent SVC response represents a new biomarker for the metabolic syndrome and the exaggerated inflammatory response, which characterizes the metabolic syndrome, may be an outcome of deficient glucocorticoid action in vascular tissue.
Assuntos
Acantose Nigricans/tratamento farmacológico , Acantose Nigricans/fisiopatologia , Resistência a Medicamentos/fisiologia , Glucocorticoides/uso terapêutico , Resistência à Insulina/fisiologia , Síndrome Metabólica/fisiopatologia , Acantose Nigricans/epidemiologia , Adulto , Beclometasona/uso terapêutico , Proteína C-Reativa/metabolismo , Estudos de Casos e Controles , Comorbidade , Estudos Transversais , Feminino , Humanos , Resistência à Insulina/etnologia , Masculino , Síndrome Metabólica/epidemiologia , Síndrome Metabólica/etnologia , Pessoa de Meia-Idade , Pele/irrigação sanguínea , Vasoconstrição/fisiologia , Índias OcidentaisRESUMO
Erythema migrans is the skin manifestation of Lyme disease and southern tick-associated rash illness. Neither disease is found in the Caribbean. We report 4 cases of erythema migrans of a possible emerging clinical entity, Caribbean erythma migrans-like illness.